Cardio Diagnostics gets contract from Vizient for heart disease tests, no terms

Cardio Diagnostics Holdings announced its AI-driven molecular heart disease tests, which identify objective epigenetic and genetic biomarkers in patients suspected to be at risk or who may have coronary heart disease, has received an Innovation Technology contract from Vizient ..The contract, which will be effective November 1, was awarded by Vizient based on a recommendation from its council of hospital experts, and it signifies to Vizient hospital and health system customers unique qualities that potentially bring improvement to the healthcare industry…”We are honored to receive this contract from Vizient, which will accelerate access to our novel heart disease tests that leverage AI and a precision medicine approach,” said Cardio Diagnostics CEO Meesha Dogan, PhD., who is also the co-inventor of the technology behind Cardio Diagnostics. “This contract recognizes our mission to transform cardiovascular disease management through advanced diagnostics. Our team is excited to make cardiovascular care more accessible across the country through this contract.”